Member Info for Baznick

Yes it does massive, and you’ve got something else to concentrate on, enjoy the hols.

Leew I’m happier with green boxes and I’ll ignore any replies with his reference in it.

The board is looking very different this morning, black and white and an awful lot of green.

And another thing, has he got a bed as he referenced it at 9 pm and was still on the go early morning!!!

So it’s not cheap enough yet?

I had unfiltered Chaebol yesterday as 500 posts and everything seemed to evolve around him.

So GST is only a mica licence now?

Think chaebol is a dyslexic spelling of chatbot. Filtered again.

Morning Nero, liked his analysis very much, all very positive only downside being trade receivables and payables both jumped sharply, I’ve not lost my faith here, only that the timeline seems to be stretching longer than I expected.

Once again hopefully 2026 ✔️

For me, what a bargain. Am I disappointed from last January, yes, hindsight tells me I should have offloaded a few, yes, but no one has convinced me that its a dud. Downside for me is progression in valuation is very slow, but no way do I think the current mcap is a true valuation of where we are. It’s out of our control but I can only hope 2026 is our year 🤞

That is much appreciated nug1

Audavid, that is the thing that annoys me most on days like this, so if things continue at the same rate all week with transactions totalling in the region 2 to 3% by Friday the mcap would be £0

I was recommended 1blocker for ad free browsing, granted it’s for ios but has transformed my experience on lse, not sure if there’s an equivalent for android but well worth checking out👌

Abr. You can’t do it through the app. You need to log in through a browser, then on the main page down the right hand side you will see shareholder meetings, click on that then on the meeting relevant to Gendrive and submit your votes there.

I too Amers have not heard anything untoward about DN, and I’m happy to sit and wait and see what materialises after the loan, as something will need to be put in place to make sure we reach break even. He’s the most invested here and his correspondence with this bb has always stated he wants a good outcome for all investors.

Until I hear something other, he has my backing to do his best for us.

I’m beginning to think I’ve filtered everyone!

My hopes are BOD show more respect for shareholders and divulge as much as possible, progress with sales and where from, not speculation.

Notice of results

Investor presentation

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces it will release its preliminary results for the year ended 30 June 2025 on Friday, 5 December 2025.

The Company will provide a live presentation to accompany the results, presented by CEO, Gino Miele and CFO, Russ Shaw on Monday, 8 December 2025 at 2pm GMT.

The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet genedrive plc via the following link: https://www.investormeetcompany.com/genedrive-plc/register-investor

Https://www.londonstockexchange.com/news-article/GDR/results-presented-re-nhs-cyp2c19-genotype-testing/17350714

Dr Gino Miele, CEO of genedrive plc, said:

"We are pleased to report the presentation of the data underpinning the NHS CYP2C19 testing implementation guidelines, clearly highlighting the positive case for implementation of our rapid CYP2C19 testing platform. Rapid availability of test results enables actionable prescription choices and reduces the risk of less effective medications being prescribed for secondary prevention of stroke. CYP2C19 interventional testing is estimated to offer £160M of value annually to the UK NHS, with rapid CY2C19 testing estimated to release 62,500 bed days and 235,000 healthcare professional hours annually and aligns perfectly with NHS 10-year plan ambitions for realising the patient and financial benefits of shifting spending to prevention from treatment. We look forward to progressing with Integrated Care Boards (ICBs) and the Dynamic Procurement System (DPS) team to deliver our cost-saving, life-changing transformational solution to stroke patients nationally."

Encep, you’ve got to be seriously confident of success knowing the below statement.

submitting an application alone DOES NOT grant the right to continue operations after the transitional period ends

Plenty of pluses at the moment, publicity on a regular basis, approval for use, cost benefit against not using.

Looking highly likely sales will follow soon, what is the supply situation, can we supply at a sufficient rate if the demand arrives?

Surgio, that sounds very much like the Sandbox we were in before being transferred into the pathway program.

Surgio, thought that is what we have been doing since applying years ago and then transferring into the pathway?